Related Experiment Videos
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor
1Professor of Medicine, University of California San Diego, Veterans Affairs Medical Center, San Diego, California, USA.
The Journal of Family Practice
|October 10, 2017
Abstract:
Since 2005, four new GLP-1RAs (liraglutide, albiglutide, dulaglutide, and lixisenatide) and a once-weekly formulation of exenatide were approved for the treatment of persons with T2DM. Another GLP-1RA, semaglutide, is under review by the FDA, as is exenatide administered via an osmotic mini-pump.